DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...

Sortera Bio, a Cambridge biotech based on IP developed at the MRC Laboratory of Molecular Biology, has attracted big hitting ...

AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus pertuzumab reduced the ...

Danaher Corp on Thursday said it has entered a partnership with AstraZeneca PLC to develop and commercialise tools and tests for precision medicine treatments, including artificial intelligence ...

The Cambridge Independent Business Awards 2025 are now open for entry. Following the success of our inaugural awards last year, we are delighted to announce that the search is now on for the best in ...

Multinationals on China: China has set a GDP growth target of around 5% for 2025. How do you view this target and China’s ...

A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a ...

effective today. The announcement was made in compliance with Listing Rule 6.4.9 (2). Headquartered in Cambridge, UK, AstraZeneca (NASDAQ:AZN) is focused on the discovery, development, and ...

Even years later, patients whose symptoms were initially dismissed experience distrust and uncertainty with clinicians.

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

AstraZeneca and the UK's Medical Research Council have unveiled a groundbreaking collaboration which will see them working hand-in-hand in a joint research facility in Cambridge in the UK.